GKOS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GKOS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Glaukos's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for Glaukos's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Medical Devices subindustry, Glaukos's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Glaukos's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Glaukos is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Glaukos (NYSE:GKOS) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Glaukos's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Alex R. Thurman | officer: SVP & Chief Financial Officer | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
Mark J Foley | director | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Tomas Navratil | officer: Chief Development Officer | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
Gilbert H Kliman | director | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
Joseph E Gilliam | officer: CFO, SVP Corporate Development | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677 |
Marc Stapley | director | 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
Aimee S Weisner | director | ONE EDWARDS WAY, IRVINE CA 92614 |
Thomas William Burns | director, 10 percent owner, officer: Chief Executive Officer | C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
Denice Torres | director | 3 RABBIT RUN DRIVE, NEW HOPE PA 18938 |
Leana Wen | director | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
Chris M. Calcaterra | officer: Chief Commercial Officer | C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
Link William J Phd | director, 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Jonathan Silverstein | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Richard L Harrison | officer: Treasurer, CFO & Secretary | 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
From GuruFocus
By Business Wire • 03-11-2025
By GuruFocus News • 04-14-2025
By GuruFocus News • 01-23-2025
By GuruFocus News • 03-12-2025
By GuruFocus News • 02-21-2025
By GuruFocus News • 02-14-2025
By GuruFocus News • 02-21-2025
By Business Wire • 01-23-2025
By GuruFocus News • 03-03-2025
By Business Wire • 04-09-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.